SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-20-000417
Filing Date
2020-05-01
Accepted
2020-05-01 16:15:48
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss172696_sc13d.htm SC 13D 111863
2 JOINT FILING AGREEMENT ss172696_ex9901.htm EX-99.1 6231
  Complete submission text file 0000947871-20-000417.txt   119684
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Subject) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91490 | Film No.: 20841042
SIC: 2834 Pharmaceutical Preparations